Stocktoria
ALNYLAM PHARMACEUTICALS, INC. ALNY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-05-28
ALNYLAM PHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Net margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% |
| FCF margin | 12.5% | -1.9% | 2.3% | -59.1% | -85.0% |
| Return on assets | 6.3% | -6.6% | -11.5% | -31.9% | -23.4% |
| Return on equity | 39.8% | -414.6% | 199.5% | 714.9% | -145.0% |
| Debt / equity | — | — | — | — | 1.15× |
| Current ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 |
| Revenue growth | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% |
Source: SEC EDGAR filings · CIK 0001178670 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.